Finding ways to overcome resistance to carboplatin in triple-negative breast cancer
Circumventing acquired carboplatin resistance in triple-negative breast cancers
This study is looking for better treatment options for people with triple-negative breast cancer who aren't responding to carboplatin, a common chemotherapy, by testing new drug combinations to help fight the cancer more effectively.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Virginia Commonwealth University NIH-funded |
| Lab location | 1 site (Richmond, United States) |
| Project ID | NIH-10981212 on NIH RePORTER |
What this research studies
This research aims to discover new treatment strategies for patients with triple-negative breast cancer (TNBC) who have developed resistance to carboplatin, a common chemotherapy drug. The team will investigate biological pathways that can be targeted alongside existing treatments to promote cancer cell death. By using patient-derived xenograft models, they will test combinations of drugs to see which are most effective in overcoming resistance. The ultimate goal is to translate these findings into clinical options for patients facing metastatic TNBC.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with triple-negative breast cancer who have shown resistance to carboplatin treatment.
Not a fit: Patients with non-breast cancers or those whose tumors are not triple-negative may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide new treatment options for patients with carboplatin-resistant triple-negative breast cancer.
How similar studies have performed: Previous research has shown promise in targeting similar pathways in cancer treatment, suggesting potential for success in this approach.
Where this research is happening
Richmond, United States
- Virginia Commonwealth University — Richmond, United States (Active)
Researchers
- Principal investigator: Harrell, Joshua (Chuck) — Virginia Commonwealth University
- Study coordinator: Harrell, Joshua (Chuck)
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.